Press Release - January 7, 2026 Epistemic AI Analysis Reveals Strategic Business Decisions as the Leading Driver of Phase 3 Clinical Trial Terminations A new study in Nature Reviews Drug Discovery shows late-stage failure rates have doubled since 2013, shifting from scientific to strategic catalysts. Epistemic AI research shows that while global trial initiations have climbed steadily since 2013, the rate of premature terminations in critical late-stage phases has grown at an even faster pace.
Press Release - January 13, 2025 ClearView Healthcare Partners Makes Strategic Investment in Epistemic AI ClearView Healthcare Partners announced a $4 million strategic investment in Epistemic AI to advance next-generation biomedical AI platforms. This partnership will integrate Epistemic AI's EpistemicGPT technology across ClearView's service offerings, combining human expertise with AI capabilities to enhance operational efficiency and provide more sophisticated analysis for life sciences organizations.
Press Release - June 8, 2023 Epistemic AI Unveils Next-generation Biomedical GPT Technology Epistemic AI unveiled its breakthrough generative AI solution for life science professionals, today at the BIO International Convention. EpistemicGPT is a unique product that addresses the acute market need for immediate access to accurate and reliable biomedical information. It empowers researchers to interact with highly complex data in a way that was unimaginable until now.
PharmaPhorum - June 9, 2023 Epistemic AI launches biomedical GPT at BIO EpistemicGPT is the first proprietary multi-agent genAI technology specialized for the Life Sciences. Integrated with a curated network of billions of biomedical information sources through our Epistemic Knowledge Graph to help researchers tease out possible connections between different pieces of data.
Press Release - February 14, 2023 Somnus Scientific enhances their competitive intelligence with Epistemic AI Epistemic AI (EAI) welcomes Somnus Scientific as a new customer of its Research Intelligence Platform. Somnus Scientific develops novel micro-sensors that provide real-time measurement of propofol anesthesia and they will use the EAI platform to accelerate their competitive intelligence research and trend analysis.
